Benzinga

Benzinga

Benzinga

mardi, septembre 01

Gilead Sciences Inc

GILDNASDAQ
Trade with Public
Trade with Public
$149.75
3.412.33%
À la clôture: Sep 1, 5:00 PM EST
Dividende: La date ex-dividende est le dans 14 jours
AperçuActualitésPrévisions de résultatsÉvénementsObjectifs de coursDonnées financièresSentimentActionnariatDividendesComparerOptionsRapport sur les stocks

Gilead Sciences Analyst Price Targets

Wall Street analyst price targets and consensus rating for Gilead Sciences (GILD).

Price Target Range — 8 Quarters

Analyst Consensus — 23 Analysts

19Buy
4Hold
Consensus RatingBuy# Analysts23Avg. Consensus PT$135Upside to Avg. PT-9.6%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →
DateFirmAnalystActionRating ChangePrice Target
Aug 5, 2026RBC CapitalBrian AbrahamsPT RaiseSector Perform$120→$123
Aug 5, 2026Cantor FitzgeraldCarter GouldMaintainedOverweight$155
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
CNBC Halftime Report Final Trades: Airbnb, Gilead Sciences, KLA, Snowflake

Benzinga Newsdesk

PRO
RBC Capital Maintains Sector Perform on Gilead Sciences, Raises Price Target to $123

RBC Capital analyst Brian Abrahams maintains Gilead Sciences (NASDAQ:GILD) with a Sector Perform and raises the price target from $120 to $123.
Benzinga Newsdesk

PRO
Cantor Fitzgerald Reiterates Overweight on Gilead Sciences, Maintains $155 Price Target

Cantor Fitzgerald analyst Carter Gould reiterates Gilead Sciences (NASDAQ:GILD) with a Overweight and maintains $155 price target.
Benzinga Newsdesk

PRO
Needham Reiterates Buy on Gilead Sciences, Maintains $170 Price Target

Needham analyst Joseph Stringer reiterates Gilead Sciences (NASDAQ:GILD) with a Buy and maintains $170 price target.
Benzinga Newsdesk

PRO
Barclays Maintains Equal-Weight on Gilead Sciences, Lowers Price Target to $145

Barclays analyst Emily Field maintains Gilead Sciences (NASDAQ:GILD) with a Equal-Weight and lowers the price target from $155 to $145.
Benzinga Newsdesk

PRO
Morgan Stanley Maintains Overweight on Gilead Sciences, Lowers Price Target to $165

Morgan Stanley analyst Matthew Harrison maintains Gilead Sciences (NASDAQ:GILD) with a Overweight and lowers the price target from $166 to $165.
Benzinga Newsdesk

Données et API: API Benzinga · API d'actualités boursières · API de notations d'analystes · API de logo d'entreprise

Données de marché fournies par API Benzinga

Benzinga

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL

© 2026 Benzinga | All Rights Reserved